Urinary hMG (Meropur) versus recombinant FSH plus recombinant LH (Pergoveris) in IVF: a multicenter, prospective, randomized controlled trial.
To compare IVF outcome in ovarian stimulation protocols with recombinant FSH plus recombinant LH versus hMG, 122 patients were randomized into two study groups: group A, patients treated with urinary hMG, and group B, patients treated with rFSH plus rLH. The two groups proved to be comparable to the main IVF outcome (pregnancy rate, implantation rate, oocytes, and embryos quality), with an increasing risk of ovarian hyperstimulation in the Pergoveris group.
Praxi Pro Vita IVF Center of Roma, Rome, Italy.
Alessandro
A
Pacchiarotti
Marco
M
Sbracia
Antonio
A
Frega
Helmy
H
Selman
Leonardo
L
Rinaldi
Arianna
A
Pacchiarotti
D004338:Drug Combinations; D005260:Female; D005300:Fertility Agents, Female / Q000008:administration & dosage; D005307:Fertilization in Vitro; D005640:Follicle Stimulating Hormone / Q000008:administration & dosage*; D006801:Humans; D007246:Infertility / Q000628:therapy*; D007986:Luteinizing Hormone / Q000008:administration & dosage*; D008297:Male; D008596:Menotropins / Q000008:administration & dosage*; D010062:Ovulation Induction / Q000379:methods; D011247:Pregnancy; D018873:Pregnancy Rate; D011994:Recombinant Proteins / Q000008:administration & dosage
D004338:Drug Combinations; D005300:Fertility Agents, Female; D011994:Recombinant Proteins; C551396:pergoveris; D008596:Menotropins; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone